AARDVARK THERAPEUTICS, INC.
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2017-01-01
- Employees
- 11
- Market Cap
- -
Clinical Trials
5
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials
ARD-101 for Treatment of PWS: The Hunger Elimination or Reduction Objective Trial
- First Posted Date
- 2025-02-17
- Last Posted Date
- 2025-09-15
- Lead Sponsor
- Aardvark Therapeutics, Inc.
- Target Recruit Count
- 90
- Registration Number
- NCT06828861
- Locations
- 🇺🇸
Children's of Alabama, Birmingham, Alabama, United States
🇺🇸Rady Children's Hospital, Encinitas, California, United States
🇺🇸Children's Hospital of Orange Country, Orange, California, United States
A Study to Evaluate ARD-501 in Patients With Autism Spectrum Disorder
- Conditions
- Autism Spectrum Disorder
- Interventions
- Drug: High Dose ARD-501Drug: PlaceboDrug: Low Dose ARD-501
- First Posted Date
- 2023-11-13
- Last Posted Date
- 2025-05-09
- Lead Sponsor
- Aardvark Therapeutics, Inc.
- Target Recruit Count
- 5
- Registration Number
- NCT06126653
- Locations
- 🇺🇸
Center for Psychiatry and Behavioral Medicine Inc, Las Vegas, Nevada, United States
Study to Evaluate ARD-101 in Adults Receiving Bariatric Surgery
- First Posted Date
- 2022-01-31
- Last Posted Date
- 2025-02-11
- Lead Sponsor
- Aardvark Therapeutics, Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT05215847
- Locations
- 🇺🇸
Altman Clinical and Translational Research Institute, University of California, San Diego, San Diego, California, United States
A Study of Oral ARD-101 in Patients With Prader-Willi Syndrome
- First Posted Date
- 2021-12-10
- Last Posted Date
- 2025-05-09
- Lead Sponsor
- Aardvark Therapeutics, Inc.
- Target Recruit Count
- 19
- Registration Number
- NCT05153434
- Locations
- 🇺🇸
Stanford University, Palo Alto, California, United States
🇺🇸Children's Hospital Colorado, Aurora, Colorado, United States
Study to Evaluate ARD-101 in Adults With Obesity
- First Posted Date
- 2021-11-16
- Last Posted Date
- 2025-01-22
- Lead Sponsor
- Aardvark Therapeutics, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT05121441
- Locations
- 🇺🇸
Altman Clinical and Translational Research Institute, University of California, San Diego, San Diego, California, United States